Use of antidepressive medicine in Danish patients with polycystic ovary syndrome

Program: Abstracts - Orals, Featured Poster Presentations, and Posters
Session: SUN 554-573-Ovarian & Uterine Function I
Basic/Clinical
Sunday, June 16, 2013: 1:45 PM-3:45 PM
Expo Halls ABC (Moscone Center)

Poster Board SUN-562
Dorte Glintborg*1, Magda Altinok1, Rene DePont Christensen2, Jesper Hallas2 and Marianne Andersen3
1Odense University Hospital, Odense, Denmark, 2University of Southern Denmark, Odense, Denmark, 3Odense University Hospital, Denmark
Background: Quality of life is impaired in women with PCOS compared to controls, but no previous studies evaluated the use of anti-depressive medication (ADM) in a patient population with PCOS.

Aim: To compare the use of ADM in patients with PCOS vs. controls.

Methods: The study was a register based study covering the residents of the Danish County of Funen linking data from Odense Pharmacoepidemiologic Database (OPED) and Funen Patient Administrative System (FPAS), a database with data on all secondary care contacts. 1124 premenopausal women referred to our outpatient clinic during 1997 –2012 with hirsutism and/or PCOS were included (first entry at department = index date). Two control groups were established:  women from the outpatient hypertensive clinic (HT, n=301) and age-matched women from the population of Funen obtained by risk-set sampling of up to four controls per case (controls, n=4110). Using OPED, prescriptions for ADM were extracted for all subjects. Time to first treatment with ADM after cohort entry was analysed by Cox-regression. The analyses were adjusted for potential confounders present at cohort entry and age (HT only).

Results: The median age at cohort entry in PCOS, HT and controls was 29, 34 and 29 years, respectively. Among PCOS, HT and controls, 227 (20%), 74 (25%) and 633 (15%) respectively had prescriptions of ADM. The median time to first use of ADM in the PCOS, HT and control cohorts was 6.8, 6.6, and 7.2 years respectively. The adjusted hazard ratio for time to prescription of ADM for PCOS vs. HT was 1.36 (95% CI [1.02 to 1.82]), p=0.039, and for PCOS vs. controls it was 0.75 (95% CI [0.64 to 0.88], p<0.001.

Conclusion: Patients with PCOS had decreased time to first prescription of ADM compared to age matched healthy women, whereas women with hypertension had shorter time to first prescription of ADM than women with PCOS.

Nothing to Disclose: DG, MA, RDC, JH, MA

*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm